Prospective randomized trials have demonstrated that postmastectomy radiotherapy (PMRT) improves not only locoregional recurrence-free survival, but also overall survival for node-positive breast cancer patients. Subset analyses in previous trials have shown that improvement of overall survival with PMRT is not always demonstrated for patients with 1-3 positive nodes. Indications for PMRT are still marginal for patients with pathological invasion 5 cm in diameter and 1-3 positive nodes. The aim of this study was to clarify poor prognostic factors for breast cancer patients with pathological invasion size 5 cm and 1-3 positive nodes. Participants comprised 428 breast cancer patients with T1-2 tumor and 1-3 positive axillary nodes (pT1-2 N1) treated using total mastectomy without radiotherapy. Correlations between clinicopathological characteristics and 10-year Kaplan-Meier estimates of locoregional recurrence-free survival, disease-free survival, and overall survival were retrospectively analyzed. Median follow-up was 98 months. Locoregional recurrence was observed in 20 patients (4.7%), and distant recurrence was observed in 70 patients (16.4%). Disease-free survival rate was 80.8%, and overall survival rate within the study period was 90%. Multivariate analysis demonstrated that favorable prognostic factors for locoregional recurrence-free survival were the presence of chemotherapy and positive hormone receptor status, and for disease-free survival were presence of chemotherapy, pT1 tumor, and single positive node. Physicians may consider these favorable prognostic factors in decision to eliminate PMRT from patients with the borderline indications. The aim of the present study was to clarify the subgroup of T1-2N1 breast cancer patients with poor prognoses for whom PMRT should be recommended.
indicate that clinicians should "strongly consider" PMRT for patients with tumors 5 cm in diameter and 1-3 positive lymph nodes, 3 whereas the 2001 American Society of Clinical Oncology guidelines did not recommend PMRT for the same patients. 4 The latest metaanalysis from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) also demonstrated that PMRT reduced the 10-year locoregional recurrence rate from 20.3% to 3.8%, and the 10-year breast cancer mortality rate from 50.2% to 42.3%. 5 The EBCTCG meta-analysis was based on 22 trials started between 1964 and 1986, and the latest chemotherapies and molecularly targeted therapies have reduced locoregional recurrence and breast cancer mortality rates beyond the levels reflected in the data included in that meta-analysis.
In addition, immediate breast reconstruction has become more common in the last decade. 6 Breast reconstruction significantly improves quality of life and reduces the psychosocial issues associated with mastectomy. 7 PMRT appears associated with an increased risk of reconstruction-related complications, such as implant removal 8 and fat necrosis of autologous tissue reconstructions. 8 Despite robust evidence and recommendations, only about 30%
of patients in the "strongly consider" cohort in the United States have actually received PMRT. 9 This may indicate that physicians do not consider PMRT as necessary for all T1-2N1 breast cancer patients.
The aim of the present study was to clarify the subgroup of T1-2N1 breast cancer patients with poor prognoses for whom PMRT should be recommended.
| MATERIALS AND METHODS
Eligible patients were women with invasive carcinoma of the breast who were treated with total mastectomy and axilla surgery, but without PMRT. Inclusion criteria for patients treated with surgery first were 1-3 positive axillary lymph nodes and primary tumor measuring 5 cm in diameter, and classification of disease as pathologically T1-2N1 (pT1-2N1). All patients received adjuvant or neoadjuvant systemic therapy with chemotherapy endocrine therapy, or both. In cases where the patient was treated with systemic therapy first, inclusion criteria were cT1-2N0-1 at the time treatment was started and residual tumor observed at both the primary site and 1-3 axillary lymph nodes, and classification as ypT1-2ypN1.
Patients with contralateral breast cancer were excluded from this study.
Background characteristics reviewed included menopausal sta- 
| RESULTS
A total of 428 patients were included in this study, and median duration of follow-up was 98 months. Clinicopathological findings of eligible patients are shown in Table 1 . At the time treatment started, 162 patients (38%) were premenopausal. All 6 clinically T3 (cT3) patients were treated by surgery preceding chemotherapy and diagnosed with pT2 from the resected specimen. All except 6 patients underwent axillary lymph node dissection, and those 6 patients had undergone sentinel lymph node biopsy without axillary lymph node dissection, because intraoperative diagnosis of sentinel nodes sug- From Tables 2-4 (Table 2) , systemic therapy-first cohort (Table 3) , and surgery-first cohort ( with favorable DFS, and HG1, 2 was not significant, but tended to correlate with favorable OS (Table 5 ).
| DISCUSSION
This study examined prognostic factors for patients who had undergone total mastectomy, and the disease was classified as pT1-2N1 Radiotherapy is associated with several adverse events, including lymph edema of the arm, 16 skin dryness, radiation pneumonitis, cardiac dysfunction, secondary skin cancer, and angiosarcoma. 17 Another problem is that PMRT can lead to an increased frequency of complications in the reconstructed breast such as capsule contracture, surgicalsite infection, and skin necrosis are more likely. 18 Given the unclear balance of risks and benefits, whether PMRT is warranted for pT1-2N1 breast cancer patients remains contentious, and the latest guidelines support this contention. 19 The guidelines stated that panelists agreed that clinicians making such recommendations for individual patients should consider factors which may decrease the risk of locoregional failure, attenuate the benefit of reduced breast cancerspecific mortality, and/or increase the risk of complications resulting from PMRT. 19 EORTC SUPREMO trial will provide insights into these issues.
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